• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Altasciences Contributes to Vibegron Approval

    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

    Pfizer Selects Seven Bridges to Support RNA Sequencing Data

    ACG Launches ACG Laboratories

    Glatt and Aprecia Enter 3D-Printing Collaboration
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions

    ACG Launches ACG Laboratories

    Glatt and Aprecia Enter 3D-Printing Collaboration

    Catalent Acquires Delphi Genetics

    Almac Group Completes $7M R&D Center
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre

    AARDEX Group Partners with Pill Connect

    Phillips-Medsize and Subcuject Collaborate
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Altasciences Contributes to Vibegron Approval

    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions

    Pfizer Selects Seven Bridges to Support RNA Sequencing Data

    ACG Launches ACG Laboratories
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    Reed-Lane

    Baxter BioPharma Solutions

    test company saurabh

    Syngene
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Almac Group

    Adare Pharma Solutions

    PCI Pharma Services

    Baxter BioPharma Solutions

    Reed-Lane
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    My Head is in The Cloud(s)

    Cloud computing is making it easier to control all aspects of the global pharma production process

    My Head is in The Cloud(s)
    Related CONTENT
    • Asymchem
    • MedPharm
    • Trial Runners
    • Mogene
    • SGS Life Sciences
    Emil W. Ciurczak, DoraMaxx Consulting05.07.19
    Once upon a time, when Pharma companies performed nearly all functions in-house, life was a lot simpler. Other than raw materials purchased from sources within the country, and the packaging materials, also manufactured in the same country, all the major functions were performed by the company:
    1. All APIs were synthesized and purified, in-house;
    2. Pre-formulation studies were performed, in-house;
    3. Clinical supplies were made in-house and the trials were run by in-house staff;
    4. Formulation and scale-up work was done, in-house;
    5. Product manufacture, QC analyses, and packaging was all performed, in-house; and
    6. Finally, through the 1970s, product was stored and sent to hospitals and pharmacies from the company’s own warehouses.
    Those were the “good old days,” when the supply chain was a nearly closed loop. Records were a combination of written files and telephone chats. Oversight was, quite literally, physical oversight. A QA person would simply walk over to another floor of their building or the next building on the campus and peruse the data and records for any lot or portion, thereof. Batch records, certificates of analysis (CoAs) for raw materials and packaging materials, and such were stored in a central location and the people generating the data were readily available. This made QRM (quality risk management) quite simple, if not perfect.

    Then the good news/bad news occurred: the markets became international, making it easier to produce a product in the country where it was sold than try to export it from “home base.” While it was, in some ways, simpler to deliver the goods, other details became difficult. The smallest difficulty was the inability of the Quality staff to lay eyes upon any piece of documentation. Yes, as the years went on, more and more of the information was available on computer files, but locating them was still primitive.

    Later on, as “blockbuster” products became the norm, the sheer number of lots produced precluded a single point of production, even within a given country. Now ‘Frisbee 25mg’ was being produced at several sites within many different countries—either by wholly owned locations or contract manufacturing organizations (CMOs). This meant that the product of a single name was being produced at numerous sites, each potentially with its own sources of API and raw materials. Keeping track of cGMP adherence was becoming a nightmare. The Quality staff was now enhanced and functions such as “vendor validation” became full-time jobs. Travel between sites—much of it overseas to sites in developing countries, where concepts like GMP were, quite literally, foreign concepts, became more and more extensive, and expensive. FDA warning letters of cases where data was destroyed and product tested over and over, until passing results were obtained, became more common. In addition, it is economically impractical to station someone from QA at each CRO and CMO to assure there is compliance with the clients’ SOPs, MMFs, etc.

    On top of that, authorities (FDA, EMA, etc.) had been required to receive advance permission from the Chinese government before entering the country for an inspection. Do we suspect that maybe, just maybe there could be some “sanitization” of the facility and records prior to the site visit? Of course, not all violations or deviations are from nefarious behavior. Many “evolving” or developing nations do not have a long history of scientific training and application. Many “lightly trained” technicians are literally learning on-the-job and will make “beginner” mistakes. Hiding these mistakes—some mechanical, some computational—is often based on embarrassment, not criminal intent. Thus, what is needed is a more immediate way to obtain an overview of contract facilities, both operational and paperwork.

    The answer can be traced to the FDA’s PAT Guidance and personnel therein. When I was having a conversation with Moheb Nasr, formerly CDER, FDA, now principal of Nasr Pharma Regulatory Consulting, he described what HE would consider the best-case scenario of an FDA inspection, remembering that all comments are personal and do not reflect Agency policy. He said, in his view, the “ideal” oversight of a company, using an approved PAT/QbD-based process line, would be to call the QA manager, ask for the code to sign into the computer system from, say, 12:00PM until 3:00 PM and XX Month, 20XX, and observe the XYZ process.

    Now, why would that be considered an “inspection?” In short, any PAT/QbD-based production has been heavily validated and proven to be effective. All the in-process data up to and including RTRT (a.k.a., real-time release testing), is subject to 21CFR part 11 (Electronic Records; Electronic Signatures). That is, all data must be stored in its raw form for up to twenty years, enabling any inspector, or appropriate QA person or manager, to recall the data and apply the algorithms that convert it into “results.” That is, these data must be shown to produce the same “answers” or results when recalled from storage and challenged well after the time they were generated. [E.g., if the API value for tablet #34,506 was 20.7 mg (103.5% of label for a 30 mg tablet) last July, it should also be 20.7 mg, today, when the algorithm is applied.]

    As was mentioned above, when the QA office was within walking/driving distance of the location where these data were generated/stored, a simple “drop-in” inspection was child’s play. As production spread to other (same country) locations, it was harder, but still feasible to “drop in” on production and quality control for impromptu inspections. With the supply chain spread over several continents, surprise visits became a thing of the past. Clearly, multinational visits are becoming painfully inefficient as controls for quality for reasons beyond cost, time and personnel constraints. Of course, I seldom merely state problems without some type of suggestion for redress of the problem. I refer to a software solution.

    When LIMS (lab information management systems) were first introduced in the 1970s, the computers were, kindly stated, primitive. The large data disks, which were the size of pizza pies, needed to be replaced daily and stored for further inspection. The lab computer that I was using for NIRS research, with attached 9 Mbyte drive, surpassed the one available to the entire QC department. Today, most smart-phones far exceed the capacity and ability of departmental LIMS units of decades ago. With the international capacity of the internet and “cloud computing,” namely a third-party server with large capacity, it became quite easy to keep control of all the aspects of a production process within a company at least. As the market for better software packages was established, a number were introduced, some better and more versatile than others. One in particular with which I am familiar stands as an example of what could be accomplished within a company AND with the client-CMO relationship.

    A Lisbon-based company (4Tune Engineering) has a product named i-Risk that began its life as a solution to communications within a corporation. The purpose was to allow a QA person in, for example, Germany, to access the records in New York, allowing them to ascertain which Guidances were being followed, etc. Obviously, records of raw materials, production progress, and so on could also be examined at any time. Shortly after the introduction of the in-company version, they rolled out the version with the ability to communicate with other companies, including contract organizations such as CMOs and CROs.

    The software allows the Quality representative to check on processes, incoming raw materials, finished product analyses, and any other items necessary. Clearly, actual qualification of incoming raw materials (NIRS, Raman) is superior to a mere certificate. But, if the R.M. suppliers have been certified and even occasionally visited, the CoA will suffice.

    The process will work best if there are actual data available for each process step (PAT), but GMP measures, once validated, could be used instead. The software can immediately show the QA person the status of each step of each CMO. Some headers are Workflows, Folders and Entities. As seen in Figure 1, the board shows numerous CMOs as well as status, what happened/is happening, what was done for any circumstance, what effect the procedure had, and so forth. Any incident can be opened and details examined. While the QA personnel are still free to travel to any CMO site, this type of software allows them to follow contracted materials’ manufacture quality in real time. Welcome to the 21st Century. Maybe clouds in the sky do signal good weather?


    Figure 1: Have A Global Picture of the Effectiveness of the CMO's Risk Assessments. Copyright: 4Tune Engineering 2019



    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Related Searches
    • scale-up
    • production
    • pharma companies
    • fda
    Suggested For You
    Asymchem Asymchem
    MedPharm MedPharm
    Trial Runners Trial Runners
    Mogene Mogene
    SGS Life Sciences SGS Life Sciences
    MIDI Labs MIDI Labs
    Softweb Solutions Softweb Solutions
    Reed-Lane Reed-Lane
    Vetio Animal Health Vetio Animal Health
    The Manufacturing Revolution In Medicine The Manufacturing Revolution In Medicine
    Swissfillon Completes Successful FDA Inspection Swissfillon Completes Successful FDA Inspection
    Greenfield Global Plans for New European Mfg. HQ Greenfield Global Plans for New European Mfg. HQ
    GSK, AstraZeneca, CPI to Build Continuous Mfg. Facility GSK, AstraZeneca, CPI to Build Continuous Mfg. Facility
    Pharmaceutical Excipients Trends Pharmaceutical Excipients Trends
    The Unfolding Pharma Product Mix The Unfolding Pharma Product Mix

    Related Columns

    • Information Technology
      Probing the Limits of Pharma’s Future

      Probing the Limits of Pharma’s Future

      A retrospective on the past 20 years and a prospective on where the future will take us.
      Ben Locwin, Contributing Writer 10.15.19

    • Drug Discovery | Information Technology
      Artificial Intelligence and Machine Learning in Healthcare

      Artificial Intelligence and Machine Learning in Healthcare

      Because your summertime reading should make you a little uncomfortable.
      Ben Locwin, PhD, MBA, MS, Contributing Editor 07.15.19

    • Information Technology
      Putting Data Integrity in Quality Agreements

      Putting Data Integrity in Quality Agreements

      With growing regulatory scrutiny, sponsors are focusing more on data integrity in supplier quality agreements.
      Robert Marohn, ClinLogic, LLC 06.12.18


    • Information Technology
      New GXP Data Integrity Guidance Published by MHRA

      New GXP Data Integrity Guidance Published by MHRA

      New GXP Data Integrity Guidance Published by MHRA
      Robert Marohn, ClinLogic, LLC 04.10.18

    • cGMP Manufacture | Information Technology
      Flexible Manufacturing Strategies and Data Integrity

      Flexible Manufacturing Strategies and Data Integrity

      Making processes integral with your data handling ability
      Emil W. Ciurczak, DoraMaxx Consulting 11.07.17

    • APIs | Information Technology
      India’s Pharmaceutical Industry Outlook

      India’s Pharmaceutical Industry Outlook

      Market predicted to be worth $50B by 2020
      Dr. Gurpreet Sandhu, Reva Pharmachem 03.06.15


    Trending
    • Century Therapeutics Significantly Expands Capabilities
    • Catalent Acquires Delphi Genetics
    • Sanofi And Translate Bio Expand Vaccine Collaboration
    • RotaChrom Technologies Partners With Cyclolab
    • Inside A Vaccine Trial
    Breaking News
    • Altasciences Contributes to Vibegron Approval
    • Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement
    • Pfizer Selects Seven Bridges to Support RNA Sequencing Data
    • ACG Launches ACG Laboratories
    • Glatt and Aprecia Enter 3D-Printing Collaboration
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Clinical Trial Finds Metabolic Benefits for Polyphenols Formula
    JRF Technology Debuts Elderberry Oral Film Strip
    Danone Adds to Plant-Based Portfolio with Acquisition of Follow Your Heart Brand
    Coatings World

    Latest Breaking News From Coatings World

    Hempel Launches Sustainability Framework: Futureproof
    ChemQuest Hires Rich Gibson
    New Increase in Kynar Fluoropolymer Capacities at Arkema's Chinese Site
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Terumo to Purchase Predictive Analytics Firm Health Outcomes Sciences
    Abiomed Leader Michael Minogue Named AdvaMed Board Chairman
    TransEnterix Changes Name to Asensus Surgical
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Altasciences Contributes to Vibegron Approval
    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement
    Pfizer Selects Seven Bridges to Support RNA Sequencing Data
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Madison Reed Raises $52 Million in Financing Round
    The Estée Lauder Companies Closes Becca Cosmetics
    Afro Sheen Launches New Brand Initiatives
    Happi

    Latest Breaking News From Happi

    PBA Opposes House Bill 2325 in West Virginia
    J.R. Watkins Tackles Pain with New Lines
    RB Launches Vanish Miracle
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Lowe-Martin Adds 2 KODAK NEXFINITY Digital Presses
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Eaglewood Technologies debuts new anilox cleaning system
    INX International and VerifyMe sign supply agreement
    Soma partners with DTM Flexo Services
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    H&V Announces Price Increase
    Fiber Bond VE3 Technology Inactivates SARS-CoV-2 in HVAC Filtration Systems
    Citizens Provides $325 Million Senior Credit Facility to Nice-Pak
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    NuVasive Nabs Simplify Medical for $150M
    SeaSpine Begins Limited Launch of WaveForm TA (TLIF Articulating) 3D-Printed Interbody
    Nexus Spine Implants for Use in Spinal Surgeries Become Available
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    RFID Locks Market to Reach $9.93 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login